Literature DB >> 27397490

A review of intranasal formulations for the treatment of seizure emergencies.

Mamta Kapoor1, James C Cloyd2, Ronald A Siegel3.   

Abstract

Epileptic seizure emergencies are life-threatening conditions, which in their most severe form, status epilepticus, have a high mortality rate if not quickly terminated. Treatment requires rapid delivery of anti-epileptics such as benzodiazepines to the brain. The nasal route is attractive due to its non-invasiveness, potential for direct nose to brain delivery, high vascularity, relatively large absorptive surface area, and avoidance of intestinal/liver metabolism. However, the limited volume of the nasal cavity and poor water solubility of anti-epileptics restrict absorption, leading to insufficient therapeutic brain levels. This review covers various formulation approaches adopted to improve nasal delivery of drugs, especially benzodiazepines, used to treat seizure emergencies. Other general topics such as nasal anatomy, challenges to nasal delivery, and drug/formulation considerations for nose to brain delivery are also discussed.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Benzodiazepines; Diazepam; Epilepsy; Intranasal; Nasal delivery device; Nose-to-brain; Seizure emergencies

Mesh:

Substances:

Year:  2016        PMID: 27397490     DOI: 10.1016/j.jconrel.2016.07.001

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  24 in total

1.  Final results from a Phase 3, long-term, open-label, repeat-dose safety study of diazepam nasal spray for seizure clusters in patients with epilepsy.

Authors:  James W Wheless; Ian Miller; R Edward Hogan; Dennis Dlugos; Victor Biton; Gregory D Cascino; Michael R Sperling; Kore Liow; Blanca Vazquez; Eric B Segal; Daniel Tarquinio; Weldon Mauney; Jay Desai; Adrian L Rabinowicz; Enrique Carrazana
Journal:  Epilepsia       Date:  2021-08-21       Impact factor: 6.740

2.  Olfactory Ensheathing Cells: A Trojan Horse for Glioma Gene Therapy.

Authors:  Litia A Carvalho; Jian Teng; Renata L Fleming; Elie I Tabet; Max Zinter; Ricardo A de Melo Reis; Bakhos A Tannous
Journal:  J Natl Cancer Inst       Date:  2019-03-01       Impact factor: 13.506

3.  Bioavailability and Safety of a New Highly Concentrated Midazolam Nasal Spray Compared to Buccal and Intravenous Midazolam Treatment in Chinese Healthy Volunteers.

Authors:  Hui Wang; Jie Huang; Shuang Yang; Xing-Fei Zhang; Xiaoyan Yang; Chang Cui; Chan Zou; Li-E Li; Min Zhang; Miao-Fu Mao; Xiang Zhou; Kai-Ming Duan; Sai-Ying Wang; Guo-Ping Yang
Journal:  Neurol Ther       Date:  2022-02-07

Review 4.  Intranasal Therapy to Stop Status Epilepticus in Prehospital Settings.

Authors:  John Benfield; Alberto Musto
Journal:  Drugs R D       Date:  2018-03

5.  Optimization of Curcumin Nanocrystals as Promising Strategy for Nose-to-Brain Delivery Application.

Authors:  Angela Bonaccorso; Maria Rosa Gigliobianco; Rosalia Pellitteri; Debora Santonocito; Claudia Carbone; Piera Di Martino; Giovanni Puglisi; Teresa Musumeci
Journal:  Pharmaceutics       Date:  2020-05-23       Impact factor: 6.321

Review 6.  Strategies for Enhancing the Permeation of CNS-Active Drugs through the Blood-Brain Barrier: A Review.

Authors:  Isra' Zeiadeh; Anas Najjar; Rafik Karaman
Journal:  Molecules       Date:  2018-05-28       Impact factor: 4.411

Review 7.  Rescue therapies for seizure emergencies: current and future landscape.

Authors:  Debopam Samanta
Journal:  Neurol Sci       Date:  2021-07-16       Impact factor: 3.830

8.  Preliminary study of nanonized lamotrigine containing products for nasal powder formulation.

Authors:  Péter Gieszinger; Ildikó Csóka; Edina Pallagi; Gábor Katona; Orsolya Jójárt-Laczkovich; Piroska Szabó-Révész; Rita Ambrus
Journal:  Drug Des Devel Ther       Date:  2017-08-23       Impact factor: 4.162

9.  Pharmacokinetics and safety of VALTOCO (NRL-1; diazepam nasal spray) in patients with epilepsy during seizure (ictal/peri-ictal) and nonseizure (interictal) conditions: A phase 1, open-label study.

Authors:  Robert Edward Hogan; Daniel Tarquinio; Michael R Sperling; Pavel Klein; Ian Miller; Eric B Segal; Adrian L Rabinowicz; Enrique Carrazana
Journal:  Epilepsia       Date:  2020-04-27       Impact factor: 5.864

Review 10.  Acetylcholinesterase: The "Hub" for Neurodegenerative Diseases and Chemical Weapons Convention.

Authors:  Samir F de A Cavalcante; Alessandro B C Simas; Marcos C Barcellos; Victor G M de Oliveira; Roberto B Sousa; Paulo A de M Cabral; Kamil Kuča; Tanos C C França
Journal:  Biomolecules       Date:  2020-03-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.